Chromatin regulators with tumor suppressor properties and their alterations in human cancers

Epigenomics

Volumn 4, Issue 5, 2012, Pages 537-549

  Shu, Xing Sheng ^a   Li, Lili ^a   Tao, Qian ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

chromatin; chromatin remodeling; epigenetic; genetic; histone modification; tumor suppressor

Indexed keywords

BARRIER TO AUTOINTEGRATION FACTOR; BRG1 PROTEIN; BRM PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; HISTONE ACETYLTRANSFERASE PCAF; HISTONE DEACETYLASE 2; HISTONE DEMETHYLASE; HISTONE H1; HISTONE H2A; HISTONE H2B; HISTONE H3; HISTONE H4; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PROTEIN P53; SIGNAL TRANSDUCING ADAPTOR PROTEIN; SIRTUIN 1; SIRTUIN 2; SIRTUIN 3; TRANSFORMING GROWTH FACTOR BETA;

APOPTOSIS; CARCINOGENESIS; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CHROMATIN; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHROMATIN CONDENSATION; DNA METHYLATION; DNA REPAIR; EPIGENETICS; GENE EXPRESSION PROFILING; GENE MUTATION; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HISTONE ACETYLATION; HISTONE METHYLATION; HISTONE MODIFICATION; HISTONE PHOSPHORYLATION; HUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; REVIEW; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE; UBIQUITINATION;

ACETYLATION; ANIMALS; CHROMATIN; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHROMOSOMAL PROTEINS, NON-HISTONE; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENES, NEOPLASM; GENES, REGULATOR; GENES, TUMOR SUPPRESSOR; HISTONES; HUMANS; MUTATION; NEOPLASMS; PROMOTER REGIONS, GENETIC; TRANSCRIPTION FACTORS;

EID: 84868592742     PISSN: 17501911     EISSN: 1750192X     Source Type: Journal    
DOI: 10.2217/epi.12.50     Document Type: Review

References (124)

1. Li B, Carey M, Workman JL. The role of chromatin during transcription. Cell 128(4), 707-719 (2007). (Pubitemid 46273570)
2. Ram O, Goren A, Amit I et al. Combinatorial patterning of chromatin regulators uncovered by genome-Wide location analysis in human cells. Cell 147(7), 1628-1639 (2011).
3. Baylin SB, Ohm JE. Epigenetic gene silencing in cancer - A mechanism for early oncogenic pathway addiction? Nat. Rev. Cancer 6(2), 107-116 (2006). (Pubitemid 43361543)
4. Rodriguez-Paredes M, Esteller M. Cancer epigenetics reaches mainstream oncology. Nat. Med. 17(3), 330-339 (2011).
5. Chi P, Allis CD, Wang GG. Covalent hist one modifications - miswritten, misinterpreted and mis-erased in human cancers. Nat. Rev. Cancer 10(7), 457-469 (2010).
6. Tsai MC, Spitale RC, Chang HY. Long intergenic noncoding RNAs: New links in cancer progression. Cancer Res. 71(1), 3-7 (2011).
7. Kouzarides T. Chromatin modifications and their function. Cell 128(4), 693-705 (2007). (Pubitemid 46273577)
8. Strahl BD, Allis CD. The language of covalent hist one modifications. Nature 403(6765), 41-45 (2000). (Pubitemid 30038513)
9. Smith E, Shilatifard A. The chromatin signaling pathway: Diverse mechanisms of recruitment of hist one-modifying enzymes and varied biological outcomes. Mol. Cell 40(5), 689-701 (2010).
10. Shahbazian MD, Grunstein M. Functions of site-specific hist one acetylation and deacetylation. Annu. Rev. Biochem. 76, 75-100 (2007).
11. Minucci S, Pelicci PG. Hist one deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer 6(1), 38-51 (2006). (Pubitemid 43054973)
12. Gu W, Roeder RG. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 90(4), 595-606 (1997). (Pubitemid 27357952)
13. Ito A, Lai CH, Zhao X et al. p300/CBP-mediated p53 acetylation is commonly induced by p53-activating agents and inhibited by MDM2. EMBO J. 20(6), 1331-1340 (2001). (Pubitemid 32233973)
14. Ferrari R, Pellegrini M, Horwitz GA, Xie W, Berk AJ, Kurdistani SK. Epigenetic reprogramming by adenovirus e1a. Science 321(5892), 1086-1088 (2008).
15. Gayther SA, Batley SJ, Linger L et al. Mutations truncating the EP300 acetylase in human cancers. Nat. Genet. 24(3), 300-303 (2000). (Pubitemid 30132203)
16. Muraoka M, Konishi M, Kikuchi-Yanoshita R et al. p300 gene alterations in colorectal and gastric carcinomas. Oncogene 12(7), 1565-1569 (1996). (Pubitemid 26132043)
17. Petrij F, Giles RH, Dauwerse HG et al. Rubinstein-Taybi syndrome caused by mutations in the transcriptional co-activator CBP. Nature 376(6538), 348-351 (1995).
18. Borrow J, Stanton VP Jr, Andresen JM et al. The translocation t(8;16)(p11;p13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB-Binding protein. Nat. Genet. 14(1), 33-41 (1996).
19. Zhao LY, Liu Y, Bertos NR, Yang XJ, Liao D. PCAF is a coactivator for p73-mediated transactivation. Oncogene 22(51), 8316-8329 (2003). (Pubitemid 37485524)
20. Zhu C, Qin YR, Xie D et al. Characterization of tumor suppressive function of P300/ CBP-associated factor at frequently deleted region 3p24 in esophageal squamous cell carcinoma. Oncogene 28(31), 2821-2828 (2009).
21. Ozdag H, Batley SJ, Forsti A et al. Mutation analysis of CBP and PCAF reveals rare inactivating mutations in cancer cell lines but not in primary tumours. Br. J. Cancer 87(10), 1162-1165 (2002). (Pubitemid 35422720)
22. Halkidou K, Gaughan L, Cook S, Leung HY, Neal DE, Robson CN. Upregulation and nuclear recruitment of HDAC1 in hormOne refractory prostate cancer. Prostate 59(2), 177-189 (2004). (Pubitemid 38481229)
23. Wilson AJ, Byun DS, Popova N et al. Hist one deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. J. Biol. Chem. 281(19), 13548-13558 (2006). (Pubitemid 43855268)
24. Bolden JE, Peart MJ, JohnstOne RW. Anticancer activities of hist one deacetylase inhibitors. Nat. Rev. Drug Discov. 5(9), 769-784 (2006). (Pubitemid 44348499)
25. Ropero S, Fraga MF, Ballestar E et al. A truncating mutation of HDAC2 in human cancers confers resistance to hist one deacetylase inhibition. Nat. Genet. 38(5), 566-569 (2006).
26. Frolov MV, Dyson NJ. Molecular mechanisms of E2F-dependent activation and pRB-mediated repression. J. Cell. Sci. 117(PT11), 2173-2181 (2004). (Pubitemid 38807486)
27. Rodriguez RM, Fraga MF. Aging and cancer: Are sirtuins the link? Future Oncol. 6(6), 905-915 (2010).
28. Saunders LR, Verdin E. Sirtuins: Critical regulators at the crossroads between cancer and aging. Oncogene 26(37), 5489-5504 (2007). (Pubitemid 47255930)
29. Wang RH, Sengupta K, Li C et al. Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice. Cancer Cell 14(4), 312-323 (2008).
30. Powell MJ, Casimiro MC, Cordon-Cardo C et al. Disruption of a Sirt1-dependent autophagy checkpoint in the prostate results in prostatic intraepithelial neoplasia lesion formation. Cancer Res. 71(3), 964-975 (2010).
31. Kim HS, Vassilopoulos A, Wang RH et al. SIRT2 maintains genome integrity and suppresses tumorigenesis through regulating APC/C activity. Cancer Cell 20(4), 487-499 (2011).
32. Finley LW, Carracedo A, Lee J et al. SIRT3 opposes reprogramming of cancer cell metabolism through HIF1α destabilization. Cancer Cell 19(3), 416-428 (2011).
33. Semenza GL. HIF-1: Upstream and downstream of cancer metabolism. Curr. Opin. Genet. Dev. 20(1), 51-56 (2010).
34. Kim HS, Patel K, Muldoon-Jacobs K et al. SIRT3 is a mitochondria- localized tumor suppressor required for maintenance of mitochondrial integrity and metabolism during stress. Cancer Cell 17(1), 41-52 (2010).
35. Mosammaparast N, Shi Y. Reversal of hist one methylation: Biochemical and molecular mechanisms of hist one demethylases. Annu. Rev. Biochem. 79, 155-179 (2010).
36. Beisel C, Paro R. Silencing chromatin: Comparing modes and mechanisms. Nat. Rev. Genet. 12(2), 123-135 (2011).
37. He L, Yu JX, Liu L et al. RIZ1, but not the alternative RIZ2 product of the same gene, is underexpressed in breast cancer, and forced RIZ1 expression causes G2-M cell cycle arrest and/or apoptosis. Cancer Res. 58(19), 4238-4244 (1998). (Pubitemid 28450017)
38. Kim KC, Geng L, Huang S. Inactivation of a hist one methyltransferase by mutations in human cancers. Cancer Res. 63(22), 7619-7623 (2003). (Pubitemid 37466684)
39. Du Y, Carling T, Fang W, Piao Z, Sheu JC, Huang S. Hypermethylation in human cancers of the RIZ1 tumor suppressor gene, a member of a hist one/protein methyltransferase superfamily. Cancer Res. 61(22), 8094-8099 (2001). (Pubitemid 33091596)
40. Oshimo Y, Oue N, Mitani Y et al. Frequent epigenetic inactivation of RIZ1 by promoter hypermethylation in human gastric carcinoma. Int. J. Cancer 110(2), 212-218 (2004). (Pubitemid 38580393)
41. Xie P, Tian C, An L et al. Hist one methyltransferase protein SETD2 interacts with p53 and selectively regulates its downstream genes. Cell Signal 20(9), 1671-1678 (2008).
42. Chuikov S, Kurash JK, Wilson JR et al. Regulation of p53 activity through lysine methylation. Nature 432(7015), 353-360 (2004). (Pubitemid 39551664)
43. Lehnertz B, Rogalski JC, Schulze FM et al. p53-dependent transcription and tumor suppression are not affected in Set7/9-deficient mice. Mol. Cell 43(4), 673-680 (2011).
44. Al Sarakbi W, Sasi W, Jiang WG, Roberts T, Newbold RF, Mokbel K. The mRNA expression of SETD2 in human breast cancer: Correlation with clinico-Pathological parameters. BMC Cancer 9, 290 (2009).
45. Dalgliesh GL, Furge K, Greenman C et al. Systematic sequencing of renal carcinoma reveals inactivation of hist one modifying genes. Nature 463(7279), 360-363 (2010).
46. Duns G, van den Berg E, van Duivenbode I et al. Hist one methyltransferase gene SETD2 is a novel tumor suppressor gene in clear cell renal cell carcinoma. Cancer Res. 70(11), 4287-4291 (2010).
47. Zhang J, Ding L, Holmfeldt L et al. The genetic basis of early T-Cell precursor acute lymphoblastic leukaemia. Nature 481(7380), 157-163 (2012).
48. Morishita M, di Luccio E. Cancers and the NSD family of hist one lysine methyltransferases. Biochim. Biophys. Acta 1816(2), 158-163 (2011).
49. Marango J, Shimoyama M, Nishio H et al. The MMSET protein is a hist one methyltransferase with characteristics of a transcriptional corepressor. Blood 111(6), 3145-3154 (2008).
50. Berdasco M, Ropero S, Setien F et al. Epigenetic inactivation of the Sotos overgrowth syndrome gene hist one methyltransferase NSD1 in human neuroblastoma and glioma. Proc. Natl Acad. Sci. USA 106(51), 21830-21835 (2009).
51. Kim SM, Kee HJ, Choe N, Kim JY, Kook H, Seo SB. The hist one methyltransferase activity of WHISTLE is important for the induction of apoptosis and HDAC1- mediated transcriptional repression. Exp. Cell Res. 313(5), 975-983 (2007). (Pubitemid 46273444)
52. Zhou Z, Thomsen R, Kahns S, Nielsen AL. The NSD3L hist one methyltransferase regulates cell cycle and cell invasion in breast cancer cells. Biochem. Biophys. Res. Commun. 398(3), 565-570 (2010).
53. Shi Y. Hist one lysine demethylases: Emerging roles in development, physiology and disease. Nat. Rev. Genet. 8(11), 829-833 (2007). (Pubitemid 47609092)
54. Shi Y, Lan F, Matson C et al. Hist one demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 119(7), 941-953 (2004). (Pubitemid 40037608)
55. Wang Y, Zhang H, Chen Y et al. LSD1 is a subunit of the NuRD complex and targets the metastasis programs in breast cancer. Cell 138(4), 660-672 (2009).
56. Hayami S, Kelly JD, Cho HS et al. Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers. Int. J. Cancer 128(3), 574-586 (2010).
57. Huang J, Sengupta R, Espejo AB et al. p53 is regulated by the lysine demethylase LSD1. Nature 449(7158), 105-108 (2007). (Pubitemid 47373772)
58. Harris WJ, Huang X, Lynch JT et al. The hist one demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells. Cancer Cell 21(4), 473-487 (2012).
59. Hong S, Cho YW, Yu LR, Yu H, Veenstra TD, Ge K. Identification of JmjC domain-Containing UTX and JMJD3 as hist one H3 lysine 27 demethylases. Proc. Natl Acad. Sci. USA 104(47), 18439-18444 (2007). (Pubitemid 350210715)
60. van Haaften G, Dalgliesh GL, Davies H et al. Somatic mutations of the hist one H3K27 demethylase gene UTX in human cancer. Nat. Genet. 41(5), 521-523 (2009).
61. Herz HM, Madden LD, Chen Z et al. The H3K27me3 demethylase dUTX is a suppressor of Notch- And Rb-dependent tumors in Drosophila. Mol. Cell. Biol. 30(10), 2485-2497 (2010).
62. Wang JK, Tsai MC, Poulin G et al. The hist one demethylase UTX enables RB-dependent cell fate control. Genes Dev. 24(4), 327-332 (2010).
63. Agger K, Cloos PA, Rudkjaer L et al. The H3K27me3 demethylase JMJD3 contributes to the activation of the INK4A-ARF locus in response to oncogene-and stress-induced senescence. Genes Dev. 23(10), 1171-1176 (2009).
64. Niu X, Zhang T, Liao L et al. The von Hippel-Lindau tumor suppressor protein regulates gene expression and tumor growth through hist one demethylase JARID1C. Oncogene 31(6), 776-786 (2011).
65. Osawa T, Muramatsu M, Wang F et al. Increased expression of hist one demethylase JHDM1D under nutrient starvation suppresses tumor growth via down-Regulating angiogenesis. Proc. Natl Acad. Sci. USA 108(51), 20725-20729 (2011).
66. Li Q, Shi L, Gui B et al. Binding of the JmjC demethylase JARID1B to LSD1/NuRD suppresses angiogenesis and metastasis in breast cancer cells by repressing chemokine CCL14. Cancer Res. 71(21), 6899-6908 (2011).
67. Nijwening JH, Geutjes EJ, Bernards R, Beijersbergen RL. The hist one demethylase Jarid1b (Kdm5b) is a novel compOnent of the Rb pathway and associates with E2f-target genes in MEFs during senescence. Plos One 6(9), e25235 (2011).
68. Ho L, Crabtree GR. Chromatin remodelling during development. Nature 463(7280), 474-484 (2010).
69. Roberts CW, Orkin SH. The SWI/SNF complex - chromatin and cancer. Nat. Rev. Cancer 4(2), 133-142 (2004). (Pubitemid 38198741)
70. Wilson BG, Roberts CW. SWI/SNF nucleosome remodellers and cancer. Nat. Rev. Cancer 11(7), 481-492 (2011).
71. Versteege I, Sevenet N, Lange J et al. Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature 394(6689), 203-206 (1998). (Pubitemid 28325977)
72. Sevenet N, Sheridan E, Amram D, Schneider P, Handgretinger R, Delattre O. Constitutional mutations of the hSNF5/INI1 gene predispose to a variety of cancers. Am. J. Hum. Genet. 65(5), 1342-1348 (1999). (Pubitemid 30460384)
73. Roberts CW, Galusha SA, McMenamin ME, Fletcher CD, Orkin SH. Haploinsufficiency of Snf5 (integrase interactor 1) predisposes to malignant rhabdoid tumors in mice. Proc. Natl Acad. Sci. USA 97(25), 13796-13800 (2000).
74. Roberts CW, Leroux MM, Fleming MD, Orkin SH. Highly penetrant, rapid tumorigenesis through conditional inversion of the tumor suppressor gene Snf5. Cancer Cell 2(5), 415-425 (2002). (Pubitemid 41039107)
75. Zhang ZK, Davies KP, Allen J et al. Cell cycle arrest and repression of cyclin D1 transcription by INI1/hSNF5. Mol. Cell. Biol. 22(16), 5975-5988 (2002). (Pubitemid 34815844)
76. Isakoff MS, Sansam CG, Tamayo P et al. Inactivation of the Snf5 tumor suppressor stimulates cell cycle progression and cooperates with p53 loss in oncogenic transformation. Proc. Natl Acad. Sci. USA 102(49), 17745-17750 (2005). (Pubitemid 41803568)
77. Wilson BG, Wang X, Shen X et al. Epigenetic antagonism between polycomb and SWI/SNF complexes during oncogenic transformation. Cancer Cell 18(4), 316-328 (2010).
78. McKenna ES, Sansam CG, Cho YJ et al. Loss of the epigenetic tumor suppressor SNF5 leads to cancer without genomic instability. Mol. Cell. Biol. 28(20), 6223-6233 (2008).
79. Yamamichi N, Yamamichi-Nishina M, Mizutani T et al. The Brm gene suppressed at the post-transcriptional level in various human cell lines is inducible by transient HDAC inhibitor treatment, which exhibits antioncogenic potential. Oncogene 24(35), 5471-5481 (2005). (Pubitemid 43080090)
80. Wong AK, Shanahan F, Chen Y et al. BRG1, a compOnent of the SWI-SNF complex, is mutated in multiple human tumor cell lines. Cancer Res. 60(21), 6171-6177 (2000).
81. Rodriguez-Nieto S, Canada A, Pros E et al. Massive parallel DNA pyrosequencing analysis of the tumor suppressor BRG1/SMARCA4 in lung primary tumors. Hum. Mutat. 32(2), e1999-e2017 (2011).
82. Bock VL, Lyons JG, Huang XX et al. BRM and BRG1 subunits of the SWI/SNF chromatin remodelling complex are downregulated upon progression of benign skin lesions into invasive tumours. Br. J. Dermatol. 164(6), 1221-1227 (2011).
83. Shen H, Powers N, Saini N et al. The SWI/SNF ATPase Brm is a gatekeeper of proliferative control in prostate cancer. Cancer Res. 68(24), 10154-10162 (2008).
84. Alessio N, Squillaro T, Cipollaro M, Bagella L, Giordano A, Galderisi U. The BRG1 ATPase of chromatin remodeling complexes is involved in modulation of mesenchymal stem cell senescence through RB-P53 pathways. Oncogene 29(40), 5452-5463 (2010).
85. Dunaief JL, Strober BE, Guha S et al. The retinoblastoma protein and BRG1 form a complex and cooperate to induce cell cycle arrest. Cell 79(1), 119-130 (1994). (Pubitemid 24309518)
86. Strobeck MW, Reisman DN, Gunawardena RW et al. Compensation of BRG-1 function by Brm: Insight into the role of the core SWI-SNF subunits in retinoblastoma tumor suppressor signaling. J. Biol. Chem. 277(7), 4782-4789 (2002). (Pubitemid 34968511)
87. Becker TM, Haferkamp S, Dijkstra MK et al. The chromatin remodelling factor BRG1 is a novel binding partner of the tumor suppressor p16INK4a. Mol. Cancer 8, 4 (2009).
88. Strobeck MW, Knudsen KE, Fribourg AF et al. BRG-1 is required for RB-mediated cell cycle arrest. Proc. Natl Acad. Sci. USA 97(14), 7748-7753 (2000). (Pubitemid 30460719)
89. Bultman SJ, Herschkowitz JI, Godfrey V et al. Characterization of mammary tumors from Brg1 heterozygous mice. Oncogene 27(4), 460-468 (2008).
90. Huang J, Zhao YL, Li Y, Fletcher JA, Xiao S. Genomic and functional evidence for an ARID1A tumor suppressor role. Genes Chromosomes Cancer 46(8), 745-750 (2007). (Pubitemid 46912345)
91. Mamo A, CavallOne L, Tuzmen S et al. An integrated genomic approach identifies ARID1A as a candidate tumor-suppressor gene in breast cancer. Oncogene 31(16), 2090-2100 (2012).
92. Jones S, Wang TL, Shih IeM et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 330(6001), 228-231 (2010).
93. Wiegand KC, Shah SP, Al-Agha OM et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N. Engl. J. Med. 363(16), 1532-1543 (2010).
94. Wang K, Kan J, Yuen ST et al. Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer. Nat. Genet. 43(12), 1219-1223 (2011).
95. Jones S, Li M, Parsons DW et al. Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types. Hum. Mutat. 33(1), 100-103 (2012).
96. Fujimoto A, Totoki Y, Abe T et al. Whole-Genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nat. Genet. 44(7), 760-764 (2012).
97. Nagl NG Jr, Zweitzig DR, Thimmapaya B, Beck GR Jr, Moran E. The c-myc gene is a direct target of mammalian SWI/SNF-Related complexes during differentiation-associated cell cycle arrest. Cancer Res. 66(3), 1289-1293 (2006). (Pubitemid 43259906)
98. Guan B, Wang TL, Shih IeM. ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers. Cancer Res. 71(21), 6718-6727 (2011).
99. Li M, Zhao H, Zhang X et al. Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma. Nat. Genet. 43(9), 828-829 (2011).
100. Yan Z, Cui K, Murray DM et al. PBAF chromatin-Remodeling complex requires a novel specificity subunit, BAF200, to regulate expression of selective interferon-Responsive genes. Genes Dev. 19(14), 1662-1667 (2005). (Pubitemid 41058360)
101. Xia W, Nagase S, Montia AG et al. BAF180 is a critical regulator of p21 induction and a tumor suppressor mutated in breast cancer. Cancer Res. 68(6), 1667-1674 (2008). (Pubitemid 351416550)
102. Varela I, Tarpey P, Raine K et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 469(7331), 539-542 (2011).
103. Drost J, Mantovani F, Tocco F et al. BRD7 is a candidate tumour suppressor gene required for p53 function. Nat. Cell. Biol. 12(4), 380-389 (2010).
104. Liu H, Zhang L, Niu Z et al. Promoter methylation inhibits BRD7 expression in human nasopharyngeal carcinoma cells. BMC Cancer 8, 253 (2008).
105. Lin JR, Zeman MK, Chen JY, Yee MC, Cimprich KA. SHPRH and HLTF act in a damage-specific manner to coordinate different forms of postreplication repair and prevent mutagenesis. Mol. Cell 42(2), 237-249 (2011).
106. Moinova HR, Chen WD, Shen L et al. HLTF gene silencing in human colon cancer. Proc. Natl Acad. Sci. USA 99(7), 4562-4567 (2002). (Pubitemid 34286024)
107. Hamai Y, Oue N, Mitani Y et al. DNA hypermethylation and hist one hypoacetylation of the HLTF gene are associated with reduced expression in gastric carcinoma. Cancer Sci. 94(8), 692-698 (2003). (Pubitemid 37160926)
108. Herbst A, Wallner M, Rahmig K et al. Methylation of helicase-like transcription factor in serum of patients with colorectal cancer is an independent predictor of disease recurrence. Eur. J. Gastroenterol. Hepatol. 21(5), 565-569 (2009).
109. Kim JJ, Chung SW, Kim JH et al. Promoter methylation of helicase-like transcription factor is associated with the early stages of gastric cancer with family history. Ann. Oncol. 17(4), 657-662 (2006).
110. Nagarajan P, Onami TM, Rajagopalan S, Kania S, Donnell R, Venkatachalam S. Role of chromodomain helicase DNA-Binding protein 2 in DNA damage response signaling and tumorigenesis. Oncogene 28(8), 1053-1062 (2009).
111. Bagchi A, Papazoglu C, Wu Y et al. CHD5 is a tumor suppressor at human 1p36. Cell 128(3), 459-475 (2007). (Pubitemid 46198889)
112. Kim MS, Chung NG, Kang MR, Yoo NJ, Lee SH. Genetic and expressional alterations of CHD genes in gastric and colorectal cancers. Histopathology 58(5), 660-668 (2011).
113. Gorringe KL, Choong DY, Williams LH et al. Mutation and methylation analysis of the chromodomain-helicase-DNA binding 5 gene in ovarian cancer. Neoplasia 10(11), 1253-1258 (2008).
114. Fujita T, Igarashi J, Okawa ER et al. CHD5, a tumor suppressor gene deleted from 1p36.31 in neuroblastomas. J. Natl Cancer Inst. 100(13), 940-949 (2008). (Pubitemid 351957513)
115. Mulero-Navarro S, Esteller M. Chromatin remodeling factor CHD5 is silenced by promoter CpG island hypermethylation in human cancer. Epigenetics 3(4), 210-215 (2008).
116. Garcia I, Mayol G, Rodriguez E et al. Expression of the neuron-specific protein CHD5 is an independent marker of outcome in neuroblastoma. Mol. Cancer 9, 277 (2010).
117. Wong RR, Chan LK, Tsang TP et al. CHD5 downregulation associated with poor prognosis in epithelial ovarian cancer. Gynecol. Obstet. Invest. 72(3), 203-207 (2011).
118. Zang ZJ, Cutcutache I, Poon SL et al. Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. Nat. Genet. 44(5), 570-574 (2012).
119. Schwartzentruber J, Korshunov A, Liu XY et al. Driver mutations in hist one H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 482(7384), 226-231 (2012).
120. Wu G, Broniscer A, McEachron TA et al. Somatic hist one H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-Brainstem glioblastomas. Nat. Genet. 44(3), 251-253 (2012).
121. Seligson DB, Horvath S, Shi T et al. Global hist one modification patterns predict risk of prostate cancer recurrence. Nature 435(7046), 1262-1266 (2005). (Pubitemid 40943093)
122. Barlesi F, GiaccOne G, Gallegos-Ruiz MI et al. Global hist one modifications predict prognosis of resected non-small-Cell lung cancer. J. Clin. Oncol. 25(28), 4358-4364 (2007). (Pubitemid 350013840)
123. Chadwick RB, Jiang GL, Bennington GA et al. Candidate tumor suppressor RIZ is frequently involved in colorectal carcinogenesis. Proc. Natl Acad. Sci. USA 97(6), 2662-2667 (2000). (Pubitemid 30159228)
124. Zhang C, Li H, Wang Y et al. Epigenetic inactivation of the tumor suppressor gene RIZ1 in hepatocellular carcinoma involves both DNA methylation and hist one modifications. J. Hepatol. 53(5), 889-895 (2010).